Oncoinvent ASA
ONCIN
Company Profile
Business description
Oncoinvent ASA is a clinical-stage company focused on developing radiopharmaceutical drugs against cancer. Its product candidate Radspherin is designed for targeted local treatment of metastatic cancers in body cavities using potent alpha radiation. It is currently evaluated in a Phase 2 randomized controlled study of ovarian cancer, building on previous encouraging safety data and signals of efficacy.
Contact
Gullhaugveien 7
Oslo0484
NORT: +47 22183305
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
34
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,467.00 | 4.40 | 0.05% |
| CAC 40 | 7,856.28 | 112.53 | 1.45% |
| DAX 40 | 23,568.39 | 69.07 | 0.29% |
| Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
| FTSE 100 | 8,601.09 | 46.29 | 0.54% |
| HKSE | 23,549.46 | 681.72 | 2.98% |
| NASDAQ | 17,928.92 | 0.78 | 0.00% |
| Nikkei 225 | 37,644.26 | 140.93 | 0.38% |
| NZX 50 Index | 12,676.75 | 71.68 | 0.57% |
| S&P 500 | 5,659.91 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,233.50 | 2.30 | 0.03% |
| SSE Composite Index | 3,369.24 | 27.25 | 0.82% |